REDMILE — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Deciphera PharmaceuticalsinMay 2017
Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.
BiotechWaltham, US
Daniel F. Flynn, Ph.D.(Executive Officer)Oliver Rosen, M.D.(Executive Officer)inThomas Kelly(Executive Officer)Michael Taylor(Executive Officer, Director)in
BoardMichael Ross(Director)Liam Ratcliffe, M.D., Ph.D.(Director)
Co-investorsFrazier Life SciencesViking GlobalViking Global Investors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.


